Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Sant P. Chawla et al.|The Lancet|2016Cited by 766
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcomaAviv Regev, Cyril Neftel, Marni E. Shore et al.|Nature Medicine|2021Cited by 127
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of boneJacob Engellau, Bruce Allen Bach, Amy Feng et al.|World Journal of Surgical Oncology|2018Cited by 56
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Clinical Cancer Research|2024Cited by 35
Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapyAnna F. Farago, Alice T. Shaw, Benjamin J. Drapkin et al.|Cancer Research|2017Cited by 9